Member Since 2021
LynkCare Inc d/b/a OncoLens
Most recently, she was the head of technology and innovation at McKesson’s Medical Surgical business unit, where she led the development and launch of several successful tools and business partnerships. Before her role at McKesson Medical Surgical, Anju was part of McKesson’s corporate strategy group. She was also co-founder and executive at LumaMed, a medical device company focused on cancer imaging. A serial entrepreneur, Anju has raised more than $8M in funding, won numerous accolades, including Women 2.0 2009 and the TAG top innovator’s award. She is very passionate about innovation and technology startups – is an active angel investor, a prior member of the Atlanta Technology Angels group, and served as a board member at technology startups. She has served in strategy and technology roles at various companies, including Thomson Reuters, A. T. Kearney, IBM, and i2 Technologies. Anju has an MBA from Northwestern University’s Kellogg School of Management and a Bachelor’s in Industrial Engineering from the Indian Institute of Technology. In her free time, Anju enjoys spending time with her family, going on long walks, watching movies, and traveling around the world.
Every professional story includes some mistakes and missteps—including the stories of successful entrepreneurs and business leaders.
OncoLens is a powerful tool for the conduct of clinical cancer conferences and care treatment planning. Our oncology focus allows us to assist our clients in optimizing patient care and making the accreditation process easier. The OncoLens platform: • Creates and manages tumor board schedules • Integrates into EMR for efficient collection of data • Allows for uploading of images from a PC or smartphone • HIPPA compliant • Provides CoC/NAPBC/NAPRC accreditation documentation • Automatically screens for clinical trial eligibility • Facilitates remote meetings • Notifies team members of outstanding items • Real-time collaboration Benefits of implementing OncoLens: • Up to a 90% decrease in tumor board time • Expedited case review • Increased number of cases reviewed • Higher quality care • Increased participation in clinical trials • Documentation needed for CoC or NAPBC accreditation